Memantine Tablet
Product Images NDC 0615-8319

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 0615-8319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 1)

Chemical structure of Memantine hydrochloride, showing its molecular framework with labeled amine and methyl groups.*

FDA Label Image

Memantine 10mg Tab Bingo Card Label (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 10)

Label for Memantine Hydrochloride Tablets USP 10 mg, supplied in a quantity of 30 tablets. The label includes multiple barcodes and lot number 8319. The tablets are packaged by Vangard Labs, Glasgow, KY 42141. Storage instructions advise to keep the product at 20°-25°C (68°-77°F) in a tight container. The label is marked for institutional use only and includes sections for receiving dates and instructions to consult the package insert for dosage information.*

FDA Label Image

Figure1 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 2)

A line graph comparing the mean change from baseline in ADCS-ADL scores over weeks of treatment between Memantine HCl and placebo groups. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis represents mean ± SEM change from baseline. The graph indicates trends towards clinical improvement or decline.*

FDA Label Image

Figure2 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 3)

A cumulative percentage plot graph showing the change from baseline in ADCS-ADL scores for patients treated with Memantine HCl compared to placebo. The x-axis represents ADCS-ADL change from baseline, and the y-axis represents the cumulative percentage of patients. The graph contrasts two groups, Memantine HCl and placebo, over the range of values shown.*

FDA Label Image

Figure3 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 4)

A line graph comparing the mean change from baseline in SIB score over 28 weeks of treatment for Memantine HCl versus placebo. The x-axis represents weeks of treatment, and the y-axis shows mean change in SIB score, with lines indicating trends toward clinical improvement or decline for both groups.*

FDA Label Image

Figure4 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 5)

A cumulative percentage graph comparing placebo and Memantine HCl responses. The x-axis represents SIB change from baseline, and the y-axis shows the cumulative percentage of patients. The graph shows two curves, one for placebo and one for Memantine HCl, illustrating patient response differences over the measured range.*

FDA Label Image

Figure5 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 6)

A line graph comparing the mean change from baseline in ADCS-ADL Score over 24 weeks of treatment between Placebo/Donepezil and Memantine HCl/Donepezil groups. The X-axis represents weeks of treatment, and the Y-axis shows the mean change score, with indicated trends toward clinical improvement and clinical decline.*

FDA Label Image

Figure6 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 7)

A line graph comparing the cumulative percentage of patients on the vertical axis with ADCS-ADL change from baseline on the horizontal axis. Two curves represent placebo/donepezil and memantine HCl/donepezil treatments, illustrating the distribution of patient responses in these groups.*

FDA Label Image

Figure7 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 8)

A line graph illustrating the mean change from baseline in ADAS-Cog score over 24 weeks of treatment for two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis measures the mean change in score, indicating clinical improvement above and clinical decline below a reference line. The x-axis represents weeks of treatment with data points and error bars shown for both groups.*

FDA Label Image

Figure8 (Memantine Hydrochloride Tabs 10mg 8319 Dr Reddys 9)

A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares the effects of placebo/donepezil and memantine HCl/donepezil with two distinct curves representing each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.